{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:59:39Z","timestamp":1790391579638,"version":"4.1.0"},"reference-count":26,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cancer Control"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>Clinician assessment of adverse events in oncology systematically underestimates the severity and frequency of symptoms that patients actually experience, creating risks in both drug development and routine care. Electronic patient-reported outcome (ePRO) systems help to address this gap by enabling frequent remote symptom monitoring, bringing the patient voice into the care pathway between clinic visits. Published studies confirm that automated data-driven alerting in response to ePRO data entries can drive better patient outcomes including reduced emergency department visits, delayed physical function deterioration, and improved symptom control, with early intervention the likely mechanism. Translating this evidence into practice demands deliberate attention to how data are visualized, communicated, and acted upon. This perspectives article examines, primarily in the context of oncology clinical trials, the tools and design principles that translate ePRO data into timely clinical action, including heatmap visualizations that reveal symptom trajectories at a glance, predefined alert thresholds that trigger proactive responses, and patient-facing self-management support delivered at the moment of reporting. The regulatory, ethical and methodological case for embedding active monitoring within oncology trial design is also considered.<\/jats:p>","DOI":"10.1177\/10732748261492633","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:06:13Z","timestamp":1790078773000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Making PRO Data Work: Remote Monitoring, Real-Time Visualization, and Timely Intervention in Oncology Trials and Patient Care"],"prefix":"10.1177","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-4271","authenticated-orcid":false,"given":"Bill","family":"Byrom","sequence":"first","affiliation":[{"name":"eCOA Science, Signant Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Everhart","sequence":"additional","affiliation":[{"name":"Science and Medicine Signant Health"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"e_1_3_4_2_2","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE): version 4.0","year":"2009","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE): version 4.0. National Cancer Institute. 2009. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf [Accessed 2026-06-01]."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.2196\/64611"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab015"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-104"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.24793"},{"key":"e_1_3_4_7_2","unstructured":"EORTC QLQ-C30 scoring manual. European Organisation for Research and Treatment of Cancer. 2001. URL. https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/SCmanual.pdf [Accessed 2026-06-01]."},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03507-y"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju244"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.20.00081"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101005"},{"key":"e_1_3_4_12_2","article-title":"Core patient-reported outcomes in cancer clinical trials: guidance for industry","author":"Food and Drug Administration","year":"2024","unstructured":"Food and Drug Administration. Core patient-reported outcomes in cancer clinical trials: guidance for industry. Food and Drug Administration. 2024. URL. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/core-patient-reported-outcomes-cancer-clinical-trials [Accessed 2026-06-01].","journal-title":"Food and Drug Administration"},{"key":"e_1_3_4_13_2","unstructured":"FACIT Item GP5: Functional Assessment of Chronic Illness Therapy - Item GP5. FACIT. 2024. URL. https:\/\/www.facit.org\/measures\/facit-item-gp5 [Accessed 2026-06-01]."},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djad018"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-018-2020-3"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-022-00424-3"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-015-1107-3"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.21903"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.6421"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/1740774520972125"},{"key":"e_1_3_4_21_2","unstructured":"International Congress for Harmonization. Guideline for Good Clinical Practice E6 (R3) 2025. URL. https:\/\/database.ich.org\/sites\/default\/files\/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf [Accessed 2026-06-01]."},{"key":"e_1_3_4_22_2","unstructured":"European Medicines Agency. Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man The use of patient-reported outcome (PRO) measures in oncology studies. 2016. https:\/\/www.ema.europa.eu\/en\/documents\/other\/appendix-2-guideline-evaluation-anticancer-medicinal-products-man_en.pdf. [Accessed 2026-06-01]."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.44412"},{"issue":"7","key":"e_1_3_4_24_2","first-page":"643","article-title":"Associations of symptom burden with patient-reported outcomes and clinical outcomes among early phase cancer clinical trial participants","volume":"34","author":"Lam AB","year":"2026","unstructured":"Lam AB, Pelletier A, Durbin SM, et al. Associations of symptom burden with patient-reported outcomes and clinical outcomes among early phase cancer clinical trial participants. Support Care Cancer. 2026;34(7):643.","journal-title":"Support Care Cancer"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.22.00187"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.2196\/69398"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2026.103866"}],"container-title":["Cancer Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748261492633","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10732748261492633","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748261492633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:19:04Z","timestamp":1790389144000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10732748261492633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":26,"alternative-id":["10.1177\/10732748261492633"],"URL":"https:\/\/doi.org\/10.1177\/10732748261492633","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/10732748261492633\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261492633\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261492633\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261492633\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261492633\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261492633\/v1\/review2","asserted-by":"object"}]},"ISSN":["1073-2748","1526-2359"],"issn-type":[{"value":"1073-2748","type":"print"},{"value":"1526-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"article-number":"10732748261492633"}}